| 前收市價 | 273.94 |
| 開市 | 273.55 |
| 買盤 | 263.87 x 100 |
| 賣出價 | 277.44 x 200 |
| 今日波幅 | 273.38 - 279.78 |
| 52 週波幅 | 211.71 - 329.72 |
| 成交量 | |
| 平均成交量 | 2,922,322 |
| 市值 | 148.775B |
| Beta 值 (5 年，每月) | 0.60 |
| 市盈率 (最近 12 個月) | 22.23 |
| 每股盈利 (最近 12 個月) | 12.48 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 9.00 (3.24%) |
| 除息日 | 2024年5月16日 |
| 1 年預測目標價 | 306.20 |
ReutersAmgen investors await weight-loss drug data
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.
BenzingaSandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said. Sandoz received FD
ZacksWill These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
